Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients’ chance of being cured and clinicians’ therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies.
自20世纪90年代末利妥昔单抗问世以来，B细胞淋巴瘤靶向治疗领域取得了显著进展，不仅提升了患者的治愈机会，也丰富了临床医生的治疗手段。对疾病生物学及致病通路的深入理解，结合免疫表型与分子诊断技术的精进，是这些成就的重要推动力。尽管传统化疗在多数病例中仍是基础疗法，但化疗耐药性与累积毒性（尤其是造血储备耗竭）等问题凸显了个体化治疗策略的必要性。将靶向药物（尤其是单克隆抗体）与化疗相结合，已显著提高缓解率并延长生存期。当前治疗范式正经历重大转变：创新靶向疗法逐步取代细胞毒性药物，并对干细胞移植等传统挽救策略形成挑战。本综述系统考察淋巴瘤细胞新兴靶点的研究现状，并深入探讨弥漫性大B细胞淋巴瘤的创新疗法。从嵌合抗原受体T细胞到更强效的单克隆抗体、抗体-药物偶联物、双特异性抗体、免疫检查点抑制剂以及靶向细胞内通路的小分子药物，每种治疗模式都为治疗进展提供了新路径。本文旨在为未来DLBCL治疗策略的潜在发展方向提供前瞻性见解。
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
肿瘤(癌症)患者之家